GLP-1 receptor agonists and the path to sustainable obesity care
| dc.contributor.author | Manne-Goehler, Jennifer | |
| dc.contributor.author | Teufel, Felix | |
| dc.contributor.author | Venter, Willem Daniel Francois | |
| dc.date.accessioned | 2024-11-12T05:52:04Z | |
| dc.date.available | 2024-11-12T05:52:04Z | |
| dc.date.issued | 2024-10 | |
| dc.description.abstract | As of 2024, more than 1 billion people are estimated to be living with obesity worldwide. The glucagon-like peptide-1 receptor agonist (GLP-1RA) and closely related glucose-dependent insulinotropic polypeptide (GIP/GLP-1) dual agonist medication classes offer a promising strategy to treat obesity and prevent its downstream health complications. However, the optimal use of these medications is currently hindered by many unanswered questions, ranging from how best to select the optimal patients for treatment to their long-term effects to how to manage their costs. Among these is an increasingly urgent concern about the coverage and optimal treatment duration of GLP-1RAs at obesity dosing and evidence-based approaches to off-ramping, defined as the tapering or withdrawal of a GLP-1RA after this treatment period and its replacement by an alternative approach to weight maintenance. | en_US |
| dc.description.department | School of Health Systems and Public Health (SHSPH) | en_US |
| dc.description.librarian | hj2024 | en_US |
| dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
| dc.description.sponsorship | The National Institute of Diabetes and Digestive and Kidney Diseases; the Bill & Melinda Gates Foundation, South African Medical Research Council, National Institutes of Health, Unitaid, Foundation for Innovative New Diagnostics (FIND), Merck, and the Children’s Investment Fund Foundation (CIFF); previously receiving funding from US Agency for International Development; and receiving drug donations from ViiV Healthcare, Merck, Johnson & Johnson, and Gilead Sciences for investigator-led clinical studies to his institution; participating in commercial drug studies (including antiobesity medications) for Merck and Novo Nordisk; and receiving honoraria for educational talks and advisory board membership from Gilead Sciences, ViiV Healthcare, Mylan/Viatris, Merck, Adcock Ingram, Aspen, Abbott, Roche, Johnson & Johnson, Sanofi, Boehringer Ingelheim, Thermo Fisher Scientific, and Virology Education. | en_US |
| dc.description.uri | https://jamanetwork.com/journals/jamainternalmedicine/ | en_US |
| dc.identifier.citation | Manne-Goehler, J., Teufel, F. & Venter, W.D.F. GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care.JAMA Internal Medicine, vol. 184, no. 12, pp. 8-10, 2024. doi: 10.1001/jamainternmed.2024.3579. | en_US |
| dc.identifier.issn | 2168-6106 (print) | |
| dc.identifier.issn | 2168-6114 (online) | |
| dc.identifier.other | 10.1001/jamainternmed.2024.3579 | |
| dc.identifier.uri | http://hdl.handle.net/2263/99014 | |
| dc.language.iso | en | en_US |
| dc.publisher | American Medical Association | en_US |
| dc.rights | © 2024 American Medical Association. All rights reserved. | en_US |
| dc.subject | Obesity | en_US |
| dc.subject | Glucagon-like peptide-1 receptor agonist (GLP-1RA) | en_US |
| dc.subject | Glucose-dependent insulinotropic polypeptide (GIP/GLP-1) | en_US |
| dc.subject | Health complications | en_US |
| dc.subject | SDG-03: Good health and well-being | en_US |
| dc.subject | Viewpoint | en_US |
| dc.title | GLP-1 receptor agonists and the path to sustainable obesity care | en_US |
| dc.type | Postprint Article | en_US |